Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

The Clinical Cancer Letter, September 2011. Vol. 34, No. 9.

publication date: Sep 29, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
  • Afinitor and Exemestane More than Doubles PFS, Reduces Progression Risk by 57 Percent
  • Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent
  • Two-Step Matching Process Increases Stem-Cell Transplant Success in Blood Cancers
  • FDA News: Zofran Label Change Includes Warnings of QT Prolongation
  • NCI CTEP Trials Approved for the month of September


To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.